Single-Use Bioreactor Market, By Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), By Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, and Recombinant Proteins), By End User (Pharmaceutical and Biopharmaceutical Industries, Contract Research Organizations, Academic & Research Institutes, and Other End Users), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI5358

Pages :170

Formats :

Excel and PDF

Industry : Biotechnology

Single-Use Bioreactor Market Size and Trends

The Single Use Bioreactor Market is estimated to be valued at USD 4.15 Billion in 2025 and is expected to reach USD 13.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18% from 2025 to 2032.

Single-Use Bioreactor Market Key Factors

To learn more about this report, Request sample copy

The market growth is driven by growth in the biopharmaceutical industry and advantages of single-use technologies over stainless steel bioreactors. The trend in the single use bioreactor market has been rising adoption rates across small companies and contract manufacturing organizations. Traditionally, large biopharma companies were the primary adopters of single-use bioreactors due to high capital investment required for stainless steel bio reactors. However, small biotech startups and contract pharma manufacturing players now see single-use bioreactors as advantageous due to low installation and maintenance costs. This has allowed these entities to benefit from the flexibility of single-use bioreactors. Going forward, this trend is expected to continue and drive the market growth during the forecast period.

Advancements in Single-Use Bioreactors

The demand for single-use bioreactors is growing significantly among pharmaceutical companies as they look to streamline their drug production processes. A major driver pushing this adoption is the operation and manufacturing advantages offered by single-use bioreactors over their stainless-steel counterparts. Pharmaceutical companies are dealing with greater regulatory requirements today to ensure drug safety and quality. With single-use bioreactors, they can reduce the risks of cross-contamination between different drug batches as each bioreactor is used only once. This helps improve compliance with stringent cGMP guidelines.

Noteworthy advancements are underway in the single-use bioreactor sector, driving the market expansion. For instance, in March 2021, Thermo Fisher Scientific introduced the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. These vessels share the same footprint, featuring simplified hardware optimized for perfusion cell culture processes, thereby aiding in conserving manufacturing suite space. These advancements are expected to propel the market growth in the foreseeable future.